StreetInsider.com News Articles

Form 4 Atara Biotherapeutics, For: Mar 02 Filed by: Nguyen AnhCo

Wed, 04 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260304/26111665.html

Form 4 Atara Biotherapeutics, For: Mar 02 Filed by: Nguyen AnhCo

Wed, 04 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260304/26111665.html

Form 4 Atara Biotherapeutics, For: Mar 02 Filed by: Grant-Huerta Yanina

Wed, 04 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260304/26111671.html

Form 4 Atara Biotherapeutics, For: Mar 02 Filed by: Grant-Huerta Yanina

Wed, 04 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260304/26111671.html

Form 8-K Atara Biotherapeutics, For: Mar 03

Tue, 03 Mar 2026 08:30:00 -0500

si-local-file:///var/storage/secattach/20260303/26097194.html

Form 8-K Atara Biotherapeutics, For: Mar 03

Tue, 03 Mar 2026 08:30:00 -0500

si-local-file:///var/storage/secattach/20260303/26097194.html

Atara partner requests FDA meeting on rejected therapy application

Tue, 03 Mar 2026 08:06:17 -0500

Atara Biotherapeutics Inc. (NASDAQ: ATRA) announced that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the FDA regarding tabelecleucel, following a Complete Response Letter dated January 9, 2026.

Pierre Fabre Pharmaceuticals submitted a briefing book to the FDA addressing points from the rejection letter, according to a press release from Atara. The briefing book provides additional context and clarification that the ALLELE study was adequate, well-controlled, and sufficient to support the tabelecleucel Biologics License Application.

The briefing book includes summaries of updated, longer-term efficacy data from ALLELE, additional supportive data from the tabelecleucel development program, and post-marketing data

Atara partner requests FDA meeting on rejected therapy application

Tue, 03 Mar 2026 08:06:17 -0500

The briefing book includes summaries of updated, longer-term efficacy data from ALLELE, additional supportive data from the tabelecleucel development program, and post-marketing data

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Tue, 03 Mar 2026 08:05:00 -0500

Pierre Fabre Pharmaceuticals, in partnership with Atara, submitted a briefing book to the FDA addressing the points from the Complete Response Letter dated January 9, 2026, providing additional context and clarification that the ALLELE study was adequate, well-controlled, and

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Tue, 03 Mar 2026 08:05:00 -0500

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Tue, 03 Mar 2026 08:05:00 -0500

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Tue, 03 Mar 2026 08:05:00 -0500

Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo

Mon, 02 Mar 2026 18:26:00 -0500

si-local-file:///var/storage/secattach/20260302/26094389.html

Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo

Mon, 02 Mar 2026 18:26:00 -0500

si-local-file:///var/storage/secattach/20260302/26094389.html

Form 144 Atara Biotherapeutics, Filed by: Grant-Huerta Yanina

Mon, 02 Mar 2026 18:24:00 -0500

si-local-file:///var/storage/secattach/20260302/26094383.html

Form 144 Atara Biotherapeutics, Filed by: Grant-Huerta Yanina

Mon, 02 Mar 2026 18:24:00 -0500

si-local-file:///var/storage/secattach/20260302/26094383.html

Form 8-K Atara Biotherapeutics, For: Feb 20

Mon, 23 Feb 2026 08:29:00 -0500

si-local-file:///var/storage/secattach/20260223/26039816.html

Form 8-K Atara Biotherapeutics, For: Feb 20

Mon, 23 Feb 2026 08:29:00 -0500

si-local-file:///var/storage/secattach/20260223/26039816.html

Atara Biotherapeutics extends $9 million payment deadline to 2028

Mon, 23 Feb 2026 08:00:39 -0500

Atara Biotherapeutics Inc. (NASDAQ: ATRA) announced it amended an agreement with HealthCare Royalty to extend the due date of a $9 million cash payment from June 30, 2026 to January 1, 2028.

The payment relates to a milestone in the company's commercialization agreement with Pierre Fabre Medicament for tabelecleucel, Atara's T-cell immunotherapy. The original purchase and sale agreement with HealthCare Royalty was signed in December 2022.

As part of the amendment, Atara issued a warrant to HealthCare Royalty to purchase up to 400,000 shares of common stock at an exercise price of $0.0001 per share. The warrant has no expiration date and

Atara Biotherapeutics extends $9 million payment deadline to 2028

Mon, 23 Feb 2026 08:00:39 -0500

Atara Biotherapeutics Inc. (NASDAQ: ATRA) announced it amended an agreement with HealthCare Royalty to extend the due date of a $9 million cash payment from June 30, 2026 to January 1, 2028.

Atara Biotherapeutics Provides a Business Update